Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.380
+0.010 (0.30%)
Aug 15, 2025, 11:02 AM - Market open
Arbutus Biopharma Employees
Arbutus Biopharma had 44 employees as of December 31, 2024. The number of employees decreased by 29 or -39.73% compared to the previous year.
Employees
44
Change (1Y)
-29
Growth (1Y)
-39.73%
Revenue / Employee
$350,364
Profits / Employee
-$1,233,000
Market Cap
647.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44 | -29 | -39.73% |
| Dec 31, 2023 | 73 | -25 | -25.51% |
| Dec 31, 2022 | 98 | 11 | 12.64% |
| Dec 31, 2021 | 87 | 9 | 11.54% |
| Dec 31, 2020 | 78 | -2 | -2.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABUS News
- 9 days ago - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus - GlobeNewsWire
- 3 months ago - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 - GlobeNewsWire
- 4 months ago - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewsWire
- 5 months ago - Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle - Market Watch
- 5 months ago - Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - GlobeNewsWire